Empiric I-131 Treatment of High Thyroglobulin Levels in Differentiated Thyroid Carcinoma After Remnant Ablation

Basit Öğe Kaydı
dc.authorid0000-0002-3650-8258
dc.authorwosidELBOGA, UMUT/AAH-1320-2020
dc.authorwosidSahin, Ertan/AAG-8999-2020
dc.contributor.authorKalender, Ebuzer
dc.contributor.authorElboğa, Umut
dc.contributor.authorÇelen, Y. Zeki
dc.contributor.authorDemir, Hasan Deniz
dc.contributor.authorŞahin, Ertan
dc.contributor.authorKaracavuş, Seyhan
dc.date.accessioned2022-05-11T14:40:20Z
dc.date.available2022-05-11T14:40:20Z
dc.date.issued2014
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractAim: The objective of this study is to establish the efficacy of empiric 1-131 treatment (EIT) given for patients whose thyroglobulin(Tg) levels remained high after ablative 1-131 treatment (AIT). Methods: Fifty-six patients (46 women, 10 men; mean age 47.4 +/- 16.8), without distant metastasis, who were treated empirically for high Tg levels after AIT in our clinic, were retrospectively studied. In all patients stimulated Tg levels before AIT (Tg I) and 6 months after AIT (Tg II) were measured. After EIT, post-therapeutic whole-body scintigraphy (PWBS) was performed to all patients. 18F-FDG PET CT was performed to patients who had negative PWBS but continued to have high Tg II levels. Results: PWBS was positive in 28 patients (50%) and negative in 28 patients (50%). Twenty-eight patients did not respond to EIT (50%), and 28 patients (50%) responded to EIT at different rates. Sixteen patients (28.6%) responded to EIT completely, and 12 patients (21.4%) responded to EIT partially. Tg I was 60.7 +/- 40 ng/ml and Tg H was 31 +/- 20.4ng/ml in responding patients, whereas Tg I was 87 ng/ml and Tg II was 114.3 +/- 106 ng/ml in unresponding ones. 18F-FDG PET CT was positive in 22 patients and negative in 6. Conclusion: Our findings, suggested that the EIT is not beneficial in patients who have higher Tg II than Tg land the cure rate is low in increasing Tg levels. The patients who have high Tg II but lower than Tg I can be treated empirically with 1-131.
dc.identifier.endpage507
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue2en_US
dc.identifier.startpage503
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8943
dc.identifier.volume30
dc.identifier.wosWOS:000335937900036
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.institutionauthorŞahin, Ertan
dc.language.isoen
dc.publisherCarbone Editore
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectEmpiric I-131 treatment
dc.subjectHigh thyroglobulin levels
dc.subjectAblative I-131 treatment
dc.subjectWhole-Body Scan
dc.subjectSerum Thyroglobulin
dc.subjectFollow-Up
dc.subjectElevated Thyroglobulin
dc.subjectPredictive-Value
dc.subjectPapillary
dc.subjectTherapy
dc.subjectCancer
dc.subjectRadioiodine
dc.subjectImpact
dc.titleEmpiric I-131 Treatment of High Thyroglobulin Levels in Differentiated Thyroid Carcinoma After Remnant Ablation
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8943.pdf
Boyut:
114.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu